Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB1097 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1		II
2		-	Calendar No. 41
3	2		119THCONGRESS
4	3		1
5	4		STSESSION S. 1097
6	5		To amend title 35, United States Code, to establish an interagency task
7	6		force between the United States Patent and Trademark Office and the
8	7		Food and Drug Administration for purposes of sharing information and
9	8		providing technical assistance with respect to patents, and for other
10	9		purposes.
11	10		IN THE SENATE OF THE UNITED STATES
12	11		MARCH24, 2025
13	12		Mr. D
14	13		URBIN(for himself, Mr. TILLIS, Mr. GRASSLEY, Mr. COONS, and Mr.
15	14		W
16	15		ELCH) introduced the following bill; which was read twice and referred
17	16		to the Committee on the Judiciary
18		-	A
19		-	PRIL10, 2025
20		-	Reported by Mr. G
21		-	RASSLEY, with amendments
22		-	[Omit the parts struck through and insert the parts printed in italic] A BILL
	17	+	A BILL
23	18		To amend title 35, United States Code, to establish an
24	19		interagency task force between the United States Patent
25	20		and Trademark Office and the Food and Drug Adminis-
26	21		tration for purposes of sharing information and providing
27	22		technical assistance with respect to patents, and for other
28	23		purposes.
29	24		Be it enacted by the Senate and House of Representa-1
30	25		tives of the United States of America in Congress assembled, 2
31		-	VerDate Sep 11 2014 19:15 Apr 11, 2025 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\S1097.RS S1097
	26	+	SECTION 1. SHORT TITLE. 3
	27	+	This Act may be cited as the ‘‘Interagency Patent 4
	28	+	Coordination and Improvement Act of 2025’’. 5
	29	+	VerDate Sep 11 2014 00:10 Mar 29, 2025 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\S1097.IS S1097
32	30		ssavage on LAPJG3WLY3PROD with BILLS 2
33		-	•S 1097 RS
34		-	SECTION 1. SHORT TITLE. 1
35		-	This Act may be cited as the ‘‘Interagency Patent 2
36		-	Coordination and Improvement Act of 2025’’. 3
37		-	SEC. 2. FINDINGS. 4
38		-	Congress finds the following: 5
39		-	(1) Decisions by the United States Patent and 6
40		-	Trademark Office relating to patents may implicate, 7
41		-	or have relevance to, information housed at or in-8
42		-	volving other Federal agencies. 9
43		-	(2) Entities submitting patent applications to 10
44		-	the United States Patent and Trademark Office may 11
45		-	also submit information to, or share information 12
46		-	with, other Federal agencies, necessitating accuracy 13
47		-	and consistency in those representations. 14
48		-	(3) Research has shown that patent examiners 15
49		-	may benefit from additional information that is 16
50		-	housed at, or is available to, Federal agencies other 17
51		-	than the United States Patent and Trademark Of-18
52		-	fice in order to assess prior art and the state of 19
53		-	science and technology. 20
54		-	(4) The Under Secretary of Commerce for In-21
55		-	tellectual Property and Director of the United States 22
56		-	Patent and Trademark Office is encouraged to work 23
57		-	with other Federal agencies. 24
58		-	VerDate Sep 11 2014 19:15 Apr 11, 2025 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\S1097.RS S1097
	31	+	•S 1097 IS
	32	+	SEC. 2. FINDINGS. 1
	33	+	Congress finds the following: 2
	34	+	(1) Decisions by the United States Patent and 3
	35	+	Trademark Office relating to patents may implicate, 4
	36	+	or have relevance to, information housed at or in-5
	37	+	volving other Federal agencies. 6
	38	+	(2) Entities submitting patent applications to 7
	39	+	the United States Patent and Trademark Office may 8
	40	+	also submit information to, or share information 9
	41	+	with, other Federal agencies, necessitating accuracy 10
	42	+	and consistency in those representations. 11
	43	+	(3) Research has shown that patent examiners 12
	44	+	may benefit from additional information that is 13
	45	+	housed at, or is available to, Federal agencies other 14
	46	+	than the United States Patent and Trademark Of-15
	47	+	fice in order to assess prior art and the state of 16
	48	+	science and technology. 17
	49	+	(4) The Under Secretary of Commerce for In-18
	50	+	tellectual Property and Director of the United States 19
	51	+	Patent and Trademark Office is encouraged to work 20
	52	+	with other Federal agencies. 21
	53	+	SEC. 3. REPORT BY UNITED STATES PATENT AND TRADE-22
	54	+	MARK OFFICE. 23
	55	+	Not later than 4 years after the date of enactment 24
	56	+	of this Act, the Under Secretary of Commerce for Intellec-25
	57	+	tual Property and Director of the United States Patent 26
	58	+	VerDate Sep 11 2014 00:10 Mar 29, 2025 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\S1097.IS S1097
59	59		ssavage on LAPJG3WLY3PROD with BILLS 3
60		-	•S 1097 RS
61		-	SEC. 3. REPORT BY UNITED STATES PATENT AND TRADE-1
62		-	MARK OFFICE. 2
63		-	Not later than 4 years after the date of enactment 3
64		-	of this Act, the Under Secretary of Commerce for Intellec-4
65		-	tual Property and Director of the United States Patent 5
66		-	and Trademark Office shall submit to the Committee on 6
67		-	the Judiciary of the Senate and the Committee on the Ju-7
68		-	diciary of the House of Representatives a report that con-8
69		-	tains— 9
70		-	(1) a description of the frequency with which— 10
71		-	(A) information is provided by the Food 11
72		-	and Drug Administration to the United States 12
73		-	Patent and Trademark Office through the 13
74		-	Interagency Task Force on Patents established 14
75		-	under section 1514 of title 35, United States 15
76		-	Code, as added by section 4(a) of this Act, or 16
77		-	under processes established by that Task Force; 17
78		-	and 18
79		-	(B) the information described in subpara-19
80		-	graph (A) is used in patent examinations; 20
81		-	(2) an identification of which methods of pro-21
82		-	viding information, as described in paragraph 22
83		-	(1)(A), and types of information so shared, are most 23
84		-	useful to patent examiners; 24
85		-	(3) any recommendations for changes to be 25
86		-	made by Congress to the mandate, funding, or oper-26
87		-	VerDate Sep 11 2014 19:15 Apr 11, 2025 Jkt 059200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\S1097.RS S1097
	60	+	•S 1097 IS
	61	+	and Trademark Office shall submit to the Committee on 1
	62	+	the Judiciary of the Senate and the Committee on the Ju-2
	63	+	diciary of the House of Representatives a report that con-3
	64	+	tains— 4
	65	+	(1) a description of the frequency with which— 5
	66	+	(A) information is provided by the Food 6
	67	+	and Drug Administration to the United States 7
	68	+	Patent and Trademark Office through the 8
	69	+	Interagency Task Force on Patents established 9
	70	+	under section 15 of title 35, United States 10
	71	+	Code, as added by section 4(a) of this Act, or 11
	72	+	under processes established by that Task Force; 12
	73	+	and 13
	74	+	(B) the information described in subpara-14
	75	+	graph (A) is used in patent examinations; 15
	76	+	(2) an identification of which methods of pro-16
	77	+	viding information, as described in paragraph 17
	78	+	(1)(A), and types of information so shared, are most 18
	79	+	useful to patent examiners; 19
	80	+	(3) any recommendations for changes to be 20
	81	+	made by Congress to the mandate, funding, or oper-21
	82	+	ations of the Task Force described in paragraph 22
	83	+	(1)(A); and 23
	84	+	(4) an identification of other Federal agencies 24
	85	+	with which the Under Secretary of Commerce for In-25
	86	+	VerDate Sep 11 2014 00:10 Mar 29, 2025 Jkt 059200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\S1097.IS S1097
88	87		ssavage on LAPJG3WLY3PROD with BILLS 4
89		-	•S 1097 RS
90		-	ations of the Task Force described in paragraph 1
91		-	(1)(A); and 2
92		-	(4) an identification of other Federal agencies 3
93		-	with which the Under Secretary of Commerce for In-4
94		-	tellectual Property and Director of the United States 5
95		-	Patent and Trademark Office should explore oppor-6
96		-	tunities for coordination that are similar to those 7
97		-	undertaken with the Food and Drug Administration 8
98		-	through the activities of the Task Force described in 9
99		-	paragraph (1)(A). 10
100		-	SEC. 4. INTERAGENCY TASK FORCE ON PATENTS. 11
	88	+	•S 1097 IS
	89	+	tellectual Property and Director of the United States 1
	90	+	Patent and Trademark Office should explore oppor-2
	91	+	tunities for coordination that are similar to those 3
	92	+	undertaken with the Food and Drug Administration 4
	93	+	through the activities of the Task Force described in 5
	94	+	paragraph (1)(A). 6
	95	+	SEC. 4. INTERAGENCY TASK FORCE ON PATENTS. 7
101	96		(a) I
102		-	NGENERAL.—Chapter 1 of title 35, United 12
103		-	States Code, is amended— 13
104		-	(1) in section 2(c), by adding at the end the fol-14
105		-	lowing: 15
106		-	‘‘(6)(A) In exercising the Director’s powers and du-16
107		-	ties under this section relating to patents, and decisions 17
108		-	or actions involving patents, for human drugs and biologi-18
109		-	cal products, the Director shall, through the Interagency 19
110		-	Task Force on Patents established under section
111		-	1514, 20
112		-	consult with the Commissioner of Food and Drugs in the 21
113		-	manner described in that section. 22
114		-	‘‘(B) For purposes of subparagraph (A), the term 23
115		-	‘decisions or actions involving patents’ means decisions or 24
116		-	VerDate Sep 11 2014 19:15 Apr 11, 2025 Jkt 059200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6201 E:\BILLS\S1097.RS S1097
	97	+	NGENERAL.—Chapter 1 of title 35, United 8
	98	+	States Code, is amended— 9
	99	+	(1) in section 2(c), by adding at the end the fol-10
	100	+	lowing: 11
	101	+	‘‘(6)(A) In exercising the Director’s powers and du-12
	102	+	ties under this section relating to patents, and decisions 13
	103	+	or actions involving patents, for human drugs and biologi-14
	104	+	cal products, the Director shall, through the Interagency 15
	105	+	Task Force on Patents established under section 15, con-16
	106	+	sult with the Commissioner of Food and Drugs in the 17
	107	+	manner described in that section. 18
	108	+	‘‘(B) For purposes of subparagraph (A), the term 19
	109	+	‘decisions or actions involving patents’ means decisions or 20
	110	+	actions taken with respect to patents under this title.’’; 21
	111	+	and 22
	112	+	(2) by adding at the end the following: 23
	113	+	VerDate Sep 11 2014 00:10 Mar 29, 2025 Jkt 059200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6201 E:\BILLS\S1097.IS S1097
117	114		ssavage on LAPJG3WLY3PROD with BILLS 5
118		-	•S 1097 RS
119		-	actions taken with respect to patents under this title.’’; 1
120		-	and 2
121		-	(2) by adding at the end the following: 3
122		-	‘‘§
123		-	1514. Interagency Task Force on Patents 4
	115	+	•S 1097 IS
	116	+	‘‘§ 15. Interagency Task Force on Patents 1
124	117		‘‘(a) E
125		-	STABLISHMENT.—There is established an 5
126		-	interagency task force, to be known as the Interagency 6
127		-	Task Force on Patents (referred to in this section as the 7
128		-	‘task force’), to coordinate efforts between the Director 8
129		-	and the Commissioner of Food and Drugs (referred to in 9
130		-	this section as the ‘Commissioner’) regarding communica-10
131		-	tion about, evaluation of, and effective implementation of 11
132		-	the activities of the Office and the Food and Drug Admin-12
133		-	istration with respect to patents, and decisions or actions 13
134		-	involving patents (as defined in section 2(c)(6)(B)), for 14
135		-	human drugs and biological products. 15
	118	+	STABLISHMENT.—There is established an 2
	119	+	interagency task force, to be known as the Interagency 3
	120	+	Task Force on Patents (referred to in this section as the 4
	121	+	‘task force’), to coordinate efforts between the Director 5
	122	+	and the Commissioner of Food and Drugs (referred to in 6
	123	+	this section as the ‘Commissioner’) regarding communica-7
	124	+	tion about, evaluation of, and effective implementation of 8
	125	+	the activities of the Office and the Food and Drug Admin-9
	126	+	istration with respect to patents, and decisions or actions 10
	127	+	involving patents (as defined in section 2(c)(6)(B)), for 11
	128	+	human drugs and biological products. 12
136	129		‘‘(b) M
137		-	EMORANDUM OF UNDERSTANDING.—The Di-16
138		-	rector and the Commissioner shall enter into a memo-17
139		-	randum of understanding, or update an existing memo-18
140		-	randum of understanding, for the purposes of imple-19
141		-	menting and carrying out the duties of the task force. 20
	130	+	EMORANDUM OF UNDERSTANDING.—The Di-13
	131	+	rector and the Commissioner shall enter into a memo-14
	132	+	randum of understanding, or update an existing memo-15
	133	+	randum of understanding, for the purposes of imple-16
	134	+	menting and carrying out the duties of the task force. 17
142	135		‘‘(c) M
143		-	EMBERSHIP.—The task force shall be com-21
144		-	prised of employees of the Office, who shall be appointed 22
145		-	by the Director, and employees of the Food and Drug Ad-23
146		-	ministration, who shall be appointed by the Commissioner, 24
147		-	who have appropriate expertise and decision-making au-25
148		-	VerDate Sep 11 2014 19:15 Apr 11, 2025 Jkt 059200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6201 E:\BILLS\S1097.RS S1097
	136	+	EMBERSHIP.—The task force shall be com-18
	137	+	prised of employees of the Office, who shall be appointed 19
	138	+	by the Director, and employees of the Food and Drug Ad-20
	139	+	ministration, who shall be appointed by the Commissioner, 21
	140	+	who have appropriate expertise and decision-making au-22
	141	+	thority regarding operational, administrative, technical, 23
	142	+	medical, pharmacological, clinical, and scientific matters 24
	143	+	to carry out the functions of the task force. 25
	144	+	VerDate Sep 11 2014 00:10 Mar 29, 2025 Jkt 059200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6201 E:\BILLS\S1097.IS S1097
149	145		ssavage on LAPJG3WLY3PROD with BILLS 6
150		-	•S 1097 RS
151		-	thority regarding operational, administrative, technical, 1
152		-	medical, pharmacological, clinical, and scientific matters 2
153		-	to carry out the functions of the task force. 3
154		-	‘‘(d) A
155		-	CTIVITIES.—The task force shall carry out the 4
156		-	following functions regarding interagency coordination to 5
157		-	promote reciprocal access of information: 6
158		-	‘‘(1) Sharing information on the general proc-7
159		-	esses of the Office and the Food and Drug Adminis-8
160		-	tration, what each such agency considers in its re-9
161		-	spective review of applications, and how each such 10
162		-	agency evaluates those applications, which may be 11
163		-	undertaken through routine and ongoing meetings, 12
164		-	workshops, and training sessions. 13
165		-	‘‘(2) Sharing information on new approvals of 14
166		-	patents, human drugs and biological products, new 15
167		-	technologies and prior art (as appropriate on a case- 16
168		-	by-case basis), and scientific trends and develop-17
169		-	ments. 18
170		-	‘‘(3) Establishing a process that requires— 19
171		-	‘‘(A) the Director to request from the 20
172		-	Commissioner (and the Commissioner to pro-21
173		-	vide to the Director, upon receiving such a re-22
174		-	quest)— 23
175		-	‘‘(i) appropriate information for use 24
176		-	by employees of the Office with responsi-25
177		-	VerDate Sep 11 2014 19:15 Apr 11, 2025 Jkt 059200 PO 00000 Frm 00006 Fmt 6652 Sfmt 6201 E:\BILLS\S1097.RS S1097
	146	+	•S 1097 IS
	147	+	‘‘(d) ACTIVITIES.—The task force shall carry out the 1
	148	+	following functions regarding interagency coordination to 2
	149	+	promote reciprocal access of information: 3
	150	+	‘‘(1) Sharing information on the general proc-4
	151	+	esses of the Office and the Food and Drug Adminis-5
	152	+	tration, what each such agency considers in its re-6
	153	+	spective review of applications, and how each such 7
	154	+	agency evaluates those applications, which may be 8
	155	+	undertaken through routine and ongoing meetings, 9
	156	+	workshops, and training sessions. 10
	157	+	‘‘(2) Sharing information on new approvals of 11
	158	+	patents, human drugs and biological products, new 12
	159	+	technologies and prior art (as appropriate on a case- 13
	160	+	by-case basis), and scientific trends and develop-14
	161	+	ments. 15
	162	+	‘‘(3) Establishing a process that requires— 16
	163	+	‘‘(A) the Director to request from the 17
	164	+	Commissioner (and the Commissioner to pro-18
	165	+	vide to the Director, upon receiving such a re-19
	166	+	quest)— 20
	167	+	‘‘(i) appropriate information for use 21
	168	+	by employees of the Office with responsi-22
	169	+	bility to examine patent applications under 23
	170	+	section 131 (referred to in this section as 24
	171	+	‘patent examiners’) regarding when certain 25
	172	+	VerDate Sep 11 2014 00:10 Mar 29, 2025 Jkt 059200 PO 00000 Frm 00006 Fmt 6652 Sfmt 6201 E:\BILLS\S1097.IS S1097
178	173		ssavage on LAPJG3WLY3PROD with BILLS 7
179		-	•S 1097 RS
180		-	~~bility~~ to ~~examine patent applications under~~ 1
181		-	~~section 131 (referred~~ to in ~~this section as~~ 2
182		-	~~‘patent examiners’) regarding when certain~~ 3
183		-	~~information relating to a human drug or~~ 4
184		-	~~biological product approval,~~ ~~which may in-~~5
185		-	~~clude updates to a label or newly approved~~ 6
186		-	~~indications, is made publicly available,~~ in-7
187		-	~~cluding when such information is posted~~ 8
188		-	~~online;~~ and 9
189		-	~~‘‘(ii) appropriate access for patent ex-~~10
190		-	~~aminers to relevant sources of product ap-~~11
191		-	~~plication, approval,~~ ~~patent, and labeling in-~~12
192		-	~~formation or communications between the~~ 13
193		-	~~Food~~ and ~~Drug Administration and~~ the 14
194		-	~~human drug or biological product sponsors~~ 15
195		-	~~that may not currently be subject to public~~ 16
196		-	~~disclosure, as appropriate~~ and ~~only to the~~ 17
197		-	~~extent necessary for~~ the ~~Office to carry out~~ 18
198		-	the ~~responsibilities~~ of the ~~Office, such as~~ 19
199		-	~~ensuring accurate representations and ac~~-20
200		-	~~cess to information on whether~~ the claimed 21
201		-	~~invention that would be the subject of the~~ 22
202		-	~~patent was on sale before~~ the ~~effective fil-~~23
203		-	~~ing date~~ of ~~the claimed invention, as de-~~24
204		-	~~scribed in section 102(a)(1); and~~ 25
205		-	VerDate Sep 11 2014 19:~~15 Apr 11~~, 2025 Jkt 059200 PO 00000 Frm 00007 Fmt 6652 Sfmt 6201 E:\BILLS\S1097.RS S1097
	174	+	•S 1097 IS
	175	+	information relating to a human drug or 1
	176	+	biological product approval, which may in-2
	177	+	clude updates to a label or newly approved 3
	178	+	indications, is made publicly available, in-4
	179	+	cluding when such information is posted 5
	180	+	online; and 6
	181	+	‘‘(ii) appropriate access for patent ex-7
	182	+	aminers to relevant sources of product ap-8
	183	+	plication, approval, patent, and labeling in-9
	184	+	formation or communications between the 10
	185	+	Food and Drug Administration and the 11
	186	+	human drug or biological product sponsors 12
	187	+	that may not currently be subject to public 13
	188	+	disclosure, as appropriate and only to the 14
	189	+	extent necessary for the Office to carry out 15
	190	+	the responsibilities of the Office, such as 16
	191	+	ensuring accurate representations and ac-17
	192	+	cess to information on whether the claimed 18
	193	+	invention that would be the subject of the 19
	194	+	patent was on sale before the effective fil-20
	195	+	ing date of the claimed invention, as de-21
	196	+	scribed in section 102(a)(1); and 22
	197	+	‘‘(B) the Office to assist the Food and 23
	198	+	Drug Administration in its ministerial role of 24
	199	+	listing patents. 25
	200	+	VerDate Sep 11 2014 00:10 Mar 29, 2025 Jkt 059200 PO 00000 Frm 00007 Fmt 6652 Sfmt 6201 E:\BILLS\S1097.IS S1097
206	201		ssavage on LAPJG3WLY3PROD with BILLS 8
207		-	•S 1097 RS
208		-	‘‘(B) the Office to assist the Food and 1
209		-	Drug Administration in its ministerial role of 2
210		-	listing patents. 3
211		-	‘‘(4) Establishing a process to ensure that, in 4
212		-	appropriate circumstances, at the request of the Di-5
213		-	rector, the Commissioner shall consult with or other-6
214		-	wise furnish specific, available information to the Of-7
215		-	fice with respect to certain applications, responses, 8
216		-	or affidavits after rejections in order to assist patent 9
217		-	examiners in carrying out the duties of those patent 10
218		-	examiners. 11
	202	+	•S 1097 IS
	203	+	‘‘(4) Establishing a process to ensure that, in 1
	204	+	appropriate circumstances, at the request of the Di-2
	205	+	rector, the Commissioner shall consult with or other-3
	206	+	wise furnish specific, available information to the Of-4
	207	+	fice with respect to certain applications, responses, 5
	208	+	or affidavits after rejections in order to assist patent 6
	209	+	examiners in carrying out the duties of those patent 7
	210	+	examiners. 8
219	211		‘‘(e) R
220		-	ULE OFCONSTRUCTION.—Nothing in sub-12
221		-	section (d)(3)(B) shall be construed as— 13
222		-	‘‘(1) directing the Office to interfere with, 14
223		-	delay, or supersede the ministerial function of the 15
224		-	Food and Drug Administration of listing patents; 16
225		-	‘‘(2) indicating the position of the Office re-17
226		-	garding the ability to assert a patent in infringement 18
227		-	litigation; or 19
228		-	‘‘(3) changing the ministerial function of the 20
229		-	Food and Drug Administration of listing patents. 21
	212	+	ULE OFCONSTRUCTION.—Nothing in sub-9
	213	+	section (d)(3)(B) shall be construed as— 10
	214	+	‘‘(1) directing the Office to interfere with, 11
	215	+	delay, or supersede the ministerial function of the 12
	216	+	Food and Drug Administration of listing patents; 13
	217	+	‘‘(2) indicating the position of the Office re-14
	218	+	garding the ability to assert a patent in infringement 15
	219	+	litigation; or 16
	220	+	‘‘(3) changing the ministerial function of the 17
	221	+	Food and Drug Administration of listing patents. 18
230	222		‘‘(f) C
231		-	ONFIDENTIALITY.— 22
	223	+	ONFIDENTIALITY.— 19
232	224		‘‘(1) I
233		-	N GENERAL.—With respect to any record 23
234		-	or other information of the Food and Drug Adminis-24
235		-	tration or the Office that is confidential, either such 25
236		-	VerDate Sep 11 2014 19:15 Apr 11, 2025 Jkt 059200 PO 00000 Frm 00008 Fmt 6652 Sfmt 6201 E:\BILLS\S1097.RS S1097
	225	+	N GENERAL.—With respect to any record 20
	226	+	or other information of the Food and Drug Adminis-21
	227	+	tration or the Office that is confidential, either such 22
	228	+	agency may share any such information with the 23
	229	+	other agency in furtherance of the activities de-24
	230	+	scribed in this section, which shall remain subject to 25
	231	+	VerDate Sep 11 2014 00:10 Mar 29, 2025 Jkt 059200 PO 00000 Frm 00008 Fmt 6652 Sfmt 6201 E:\BILLS\S1097.IS S1097
237	232		ssavage on LAPJG3WLY3PROD with BILLS 9
238		-	•S 1097 RS
239		-	agency may share any such information with the 1
240		-	other agency in furtherance of the activities de-2
241		-	scribed in this section, which shall remain subject to 3
242		-	such protections as if the information were held by 4
243		-	the Food and Drug Administration. 5
	233	+	•S 1097 IS
	234	+	such protections as if the information were held by 1
	235	+	the Food and Drug Administration. 2
244	236		‘‘(2) P
245		-	ROTOCOLS.— 6
	237	+	ROTOCOLS.— 3
246	238		‘‘(A) I
247		-	N GENERAL.—The task force shall 7
248		-	establish appropriate protocols to safeguard 8
249		-	confidentiality and prevent the inappropriate 9
250		-	disclosure of information when sharing informa-10
251		-	tion between the Office and the Food and Drug 11
252		-	Administration. 12
	239	+	N GENERAL.—The task force shall 4
	240	+	establish appropriate protocols to safeguard 5
	241	+	confidentiality and prevent the inappropriate 6
	242	+	disclosure of information when sharing informa-7
	243	+	tion between the Office and the Food and Drug 8
	244	+	Administration. 9
253	245		‘‘(B) C
254		-	ONTENTS.—The protocols estab-13
255		-	lished under subparagraph (A) shall provide 14
256		-	that— 15
257		-	‘‘(i) before sharing any information 16
258		-	described in paragraph (1), the sponsor of 17
259		-	the human drug or biological product to 18
260		-	which that information relates shall be pro-19
261		-	vided notice of that sharing by the applica-20
262		-	ble agency and with a period of 30 days to 21
263		-	consult with the agency sharing that infor-22
264		-	mation; and 23
265		-	‘‘(ii) the Director shall, in order to 24
266		-	protect against the inadvertent disclosure 25
267		-	VerDate Sep 11 2014 19:15 Apr 11, 2025 Jkt 059200 PO 00000 Frm 00009 Fmt 6652 Sfmt 6201 E:\BILLS\S1097.RS S1097
	246	+	ONTENTS.—The protocols estab-10
	247	+	lished under subparagraph (A) shall provide 11
	248	+	that— 12
	249	+	‘‘(i) before sharing any information 13
	250	+	described in paragraph (1), the sponsor of 14
	251	+	the human drug or biological product to 15
	252	+	which that information relates shall be pro-16
	253	+	vided notice of that sharing by the applica-17
	254	+	ble agency and with a period of 30 days to 18
	255	+	consult with the agency sharing that infor-19
	256	+	mation; and 20
	257	+	‘‘(ii) the Director shall, in order to 21
	258	+	protect against the inadvertent disclosure 22
	259	+	of information, maintain any information 23
	260	+	shared with the Director by the Commis-24
	261	+	sioner separate from pending patent appli-25
	262	+	VerDate Sep 11 2014 00:10 Mar 29, 2025 Jkt 059200 PO 00000 Frm 00009 Fmt 6652 Sfmt 6201 E:\BILLS\S1097.IS S1097
268	263		ssavage on LAPJG3WLY3PROD with BILLS 10
269		-	•S 1097 RS
270		-	of information, maintain any information 1
271		-	shared with the Director by the Commis-2
272		-	sioner separate from pending patent appli-3
273		-	cations and establish procedures for the 4
274		-	identification of confidential information. 5
	264	+	•S 1097 IS
	265	+	cations and establish procedures for the 1
	266	+	identification of confidential information. 2
275	267		‘‘(C) P
276		-	OTENTIAL REMEDIES .—In estab-6
277		-	lishing protocols under this paragraph, the task 7
278		-	force shall identify appropriate remedies for any 8
279		-	potential injury suffered when confidential in-9
280		-	formation is made available, including inadvert-10
281		-	ently, through the sharing of information de-11
282		-	scribed in this subsection. 12
	268	+	OTENTIAL REMEDIES .—In estab-3
	269	+	lishing protocols under this paragraph, the task 4
	270	+	force shall identify appropriate remedies for any 5
	271	+	potential injury suffered when confidential in-6
	272	+	formation is made available, including inadvert-7
	273	+	ently, through the sharing of information de-8
	274	+	scribed in this subsection. 9
283	275		‘‘(3) R
284		-	ULE OF CONSTRUCTION .—Nothing in 13
285		-	this subsection may be construed as superseding any 14
286		-	other remedy available for the unauthorized disclo-15
287		-	sure of confidential information.’’. 16
	276	+	ULE OF CONSTRUCTION .—Nothing in 10
	277	+	this subsection may be construed as superseding any 11
	278	+	other remedy available for the unauthorized disclo-12
	279	+	sure of confidential information.’’. 13
288	280		(b) T
289		-	ECHNICAL AND CONFORMINGAMENDMENT.— 17
290		-	The table of sections for chapter 1 of title 35, United 18
291		-	States Code, is amended by adding at the end the fol-19
292		-	lowing: 20
293		-	‘‘
294		-	1514. Interagency Task Force on Patents.’’.
295		-	VerDate Sep 11 2014 19:15 Apr 11, 2025 Jkt 059200 PO 00000 Frm 00010 Fmt 6652 Sfmt 6211 E:\BILLS\S1097.RS S1097
296		-	ssavage on LAPJG3WLY3PROD with BILLS VerDate Sep 11 2014 19:15 Apr 11, 2025 Jkt 059200 PO 00000 Frm 00011 Fmt 6652 Sfmt 6211 E:\BILLS\S1097.RS S1097
297		-	ssavage on LAPJG3WLY3PROD with BILLS Calendar No.
298		-	41
299		-	119
300		-	TH
301		-	CONGRESS
302		-	1
303		-	ST
304		-	S
305		-	ESSION
306		-
307		-	S. 1097 A BILL
308		-	To amend title 35, United States Code, to establish
309		-	an interagency task force between the United
310		-	States Patent and Trademark Office and the
311		-	Food and Drug Administration for purposes of
312		-	sharing information and providing technical as-
313		-	sistance with respect to patents, and for other
314		-	purposes.
315		-	A
316		-	PRIL
317		-	10, 2025
318		-	Reported with amendments
319		-	VerDate Sep 11 2014 19:15 Apr 11, 2025 Jkt 059200 PO 00000 Frm 00012 Fmt 6651 Sfmt 6651 E:\BILLS\S1097.RS S1097
	281	+	ECHNICAL AND CONFORMINGAMENDMENT.— 14
	282	+	The table of sections for chapter 1 of title 35, United 15
	283	+	States Code, is amended by adding at the end the fol-16
	284	+	lowing: 17
	285	+	‘‘15. Interagency Task Force on Patents.’’.
	286	+	Æ
	287	+	VerDate Sep 11 2014 00:10 Mar 29, 2025 Jkt 059200 PO 00000 Frm 00010 Fmt 6652 Sfmt 6301 E:\BILLS\S1097.IS S1097
320	288		ssavage on LAPJG3WLY3PROD with BILLS